In the phase III ADMIRAL trial that demonstrated the advantage of Gilteritinib over conventional salvage regimens for relapsed/refractory FLT3-mutated AML, 48 out of 247 treated patients had received prior HSCT. Here, FLT3 is linked to acute myeloid leukemia.